Exelixis (EXEL) Cash from Operations (2010 - 2026)
Exelixis (EXEL) recorded quarterly Cash from Operations of 251845000.0 in Q2 2026, down 24.49% quarter-over-quarter from 333515000.0 in Q1 2026, and up 19.11% on a YoY basis from 211437000.0 in Q2 2025.
Exelixis (EXEL) Cash from Operations (2010 - 2026) Analysis & Trends
Exelixis' Cash from Operations history runs 17 years deep, the most recent figure standing at 251845000.0 for Q2 2026.
- In Q2 2026, Cash from Operations rose 19.11% year-over-year to 251845000.0; the TTM figure through Apr 2026 stood at 924675000.0 (up 9.74% YoY), while the FY2026 annual figure was 884267000.0, up 26.33% from the prior year.
- Cash from Operations was 251845000.0 for Q2 2026 at Exelixis, down from 333515000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 333515000.0 in Q1 2026 to a low of 10571000.0 in Q4 2023.
- Historically, Cash from Operations has averaged 148942411.76 across 5 years, with a median of 119548000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations plunged 85.66% in 2023, then surged 2172.85% in 2025.
- A 5-year view of Cash from Operations shows it stood at 73694000.0 in 2022, then slumped by 85.66% to 10571000.0 in 2023, then soared by 2466.81% to 271338000.0 in 2024, then grew by 7.0% to 290322000.0 in 2025, then fell by 13.25% to 251845000.0 in 2026.
- The last three Cash from Operations figures came in at 251845000.0 (Q2 2026), 333515000.0 (Q1 2026), and 290322000.0 (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 251.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 251.85 Mn |
| Apr 3, 2026 | 251.85 Mn |
| Jan 2, 2026 | 333.52 Mn |
| Jan 2, 2026 | 333.52 Mn |
| Oct 3, 2025 | 290.32 Mn |
| Oct 3, 2025 | 290.32 Mn |
| Jul 4, 2025 | 48.99 Mn |
| Jul 4, 2025 | 48.99 Mn |
| Apr 4, 2025 | 211.44 Mn |
| Apr 4, 2025 | 211.44 Mn |
| Jan 3, 2025 | 240.26 Mn |
| Jan 3, 2025 | 240.26 Mn |
| Sep 27, 2024 | 271.34 Mn |
| Sep 27, 2024 | 271.34 Mn |
| Jun 28, 2024 | 119.55 Mn |
| Jun 28, 2024 | 119.55 Mn |
| Mar 29, 2024 | 68.82 Mn |
| Mar 29, 2024 | 68.82 Mn |
| Dec 29, 2023 | 10.57 Mn |
| Dec 29, 2023 | 10.57 Mn |